The Importance of Sphingosine Kinase in Breast Cancer: A Potential for Breast Cancer Management

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Mar 24

PMID 33758708

Citations 4

Authors

Dutt S Patel

Farrukh Ahmad

Majdi Abu Sneineh

Ravi S Patel

Sai Rohit Reddy

Adiona Llukmani

Ayat Hashim

Domonick K Gordon

Affiliations

Soon will be listed here.

Abstract

Breast cancer management includes a combination of surgery, radiation therapy, and chemotherapy. While this management has proven effective, it is not perfect. To expand the umbrella of management to resistant breast cancer tumors, researchers have explored the idea of sphingosine kinase (SphK) and sphingosine-1-phosphate (S1P) as a potential target for treatment. In this article, we review the mechanism of the sphingosine kinase/sphingosine-1-phosphate (SphK/S1P) axis along with its effect on the tumor microenvironment (TME) and compounds that have been studied inhibiting the SphK/S1P axis. We searched for relevant articles in the last five years in Medline and PubMed Central. Inclusion criteria, exclusion criteria, and quality checklists were applied to identify the most relevant articles. We compiled the information that has been summarized in the respective tables and figures provided in this review. The metabolism of sphingolipids was summarized, followed by the SphK/S1P upregulation in breast cancer cells. The variety of effects by upregulation of SphK led to an increase in inflammation, growth, and metastasis in breast cancer tumors. The increase in S1P also impacted the TME, including the cells and surrounding tissue, allowing the breast tumors to thrive. The final point made was a summary of the compounds and drugs that inhibited the SphK/S1P axis. They have proven their effectiveness and show even greater efficacy in combination with docetaxel and doxorubicin in preclinical studies. In conclusion, what is known about the SphK/S1P axis within breast cancer cells is immense but incomplete as we summarize what is known so far. Having a complete picture will allow a faster transition to application in the clinical field but clinical trials have not commenced as of yet.

Citing Articles

A spheroid whole mount drug testing pipeline with machine-learning based image analysis identifies cell-type specific differences in drug efficacy on a single-cell level.

Vitacolonna M, Bruch R, Schneider R, Jabs J, Hafner M, Reischl M BMC Cancer. 2024; 24(1):1542.

PMID: 39696122 PMC: 11658419. DOI: 10.1186/s12885-024-13329-9.

Dysregulation of Fatty Acid Metabolism in Breast Cancer and Its Targeted Therapy.

Chang Y, Du R, Xia F, Xu X, Wang H, Chen X Breast Cancer (Dove Med Press). 2024; 16:825-844.

PMID: 39628960 PMC: 11614585. DOI: 10.2147/BCTT.S496322.

Reprogramming of Lipid Metabolism Mediates Crosstalk, Remodeling, and Intervention of Microenvironment Components in Breast Cancer.

Wang J, Zhang W, Liu C, Wang L, Wu J, Sun C Int J Biol Sci. 2024; 20(5):1884-1904.

PMID: 38481820 PMC: 10929185. DOI: 10.7150/ijbs.92125.

The Critical Impact of Sphingolipid Metabolism in Breast Cancer Progression and Drug Response.

Corsetto P, Zava S, Rizzo A, Colombo I Int J Mol Sci. 2023; 24(3).

PMID: 36768427 PMC: 9916652. DOI: 10.3390/ijms24032107.

References

Singh S, Spiegel S . Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain. Adv Biol Regul. 2019; 75:100670. DOI: 10.1016/j.jbior.2019.100670. View

Shimizu Y, Furuya H, Tamashiro P, Iino K, Chan O, Goodison S . Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model. Carcinogenesis. 2017; 39(1):47-55. PMC: 5862258. DOI: 10.1093/carcin/bgx097. View

Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I . Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer. Int J Mol Sci. 2020; 21(18). PMC: 7555442. DOI: 10.3390/ijms21186708. View

El Buri A, Adams D, Smith D, Tate R, Mullin M, Pyne S . The sphingosine 1-phosphate receptor 2 is shed in exosomes from breast cancer cells and is N-terminally processed to a short constitutively active form that promotes extracellular signal regulated kinase activation and DNA synthesis in fibroblasts. Oncotarget. 2018; 9(50):29453-29467. PMC: 6047680. DOI: 10.18632/oncotarget.25658. View

Liu S, Ni C, Zhang D, Sun H, Dong X, Che N . S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer. Cell Death Dis. 2019; 10(3):200. PMC: 6393557. DOI: 10.1038/s41419-019-1411-x. View

Mukhopadhyay P, Ramanathan R, Takabe K . S1P promotes breast cancer progression by angiogenesis and lymphangiogenesis. Breast Cancer Manag. 2016; 4(5):241-244. PMC: 4900461. DOI: 10.2217/bmt.15.20. View

Hait N, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H . The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis. 2015; 4:e156. PMC: 4753524. DOI: 10.1038/oncsis.2015.16. View

Rupp T, Pelouin O, Genest L, Legrand C, Froget G, Castagne V . Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models. Transl Oncol. 2020; 14(1):100926. PMC: 7649527. DOI: 10.1016/j.tranon.2020.100926. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

10.

Alshaker H, Srivats S, Monteil D, Wang Q, Low C, Pchejetski D . Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors. Breast Cancer Res Treat. 2018; 172(1):33-43. PMC: 6208908. DOI: 10.1007/s10549-018-4900-1. View

11.

Kim E, Choi B, Kim J, Park S, Kim S, Chang E . Interleukin-22 Mediates the Chemotactic Migration of Breast Cancer Cells and Macrophage Infiltration of the Bone Microenvironment by Potentiating S1P/SIPR Signaling. Cells. 2020; 9(1). PMC: 7017200. DOI: 10.3390/cells9010131. View

12.

Sukocheva O, Furuya H, Ng M, Friedemann M, Menschikowski M, Tarasov V . Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther. 2019; 207:107464. DOI: 10.1016/j.pharmthera.2019.107464. View

13.

Yamada A, Nagahashi M, Aoyagi T, Huang W, Lima S, Hait N . ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. Mol Cancer Res. 2018; 16(6):1059-1070. PMC: 6071310. DOI: 10.1158/1541-7786.MCR-17-0353. View

14.

Alshaker H, Wang Q, Srivats S, Chao Y, Cooper C, Pchejetski D . New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. Breast Cancer Res Treat. 2017; 165(3):531-543. PMC: 5602005. DOI: 10.1007/s10549-017-4380-8. View

15.

Nazouri A, Asadpour O, Dabiri S, Pourseyedi B, Lashkarizadeh M, Zianalinejad H . High Expression of Sphingosine Kinase 1 in Estrogen and Progesterone Receptors-Negative Breast Cancer. Iran J Pathol. 2018; 12(3):218-224. PMC: 5835369. View

16.

Katsuta E, Yan L, Nagahashi M, Raza A, Sturgill J, Lyon D . Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res. 2017; 219:202-213. PMC: 5661979. DOI: 10.1016/j.jss.2017.05.101. View

17.

Maia L, Santos P, Alves P, Rodrigues C, Araujo T, Maia Y . Altered Leukocyte Sphingolipid Pathway in Breast Cancer. Int J Mol Sci. 2017; 18(12). PMC: 5751124. DOI: 10.3390/ijms18122521. View

18.

Sakharkar M, Dhillon S, Chidambaram S, Essa M, Yang J . Gene Pair Correlation Coefficients in Sphingolipid Metabolic Pathway as a Potential Prognostic Biomarker for Breast Cancer. Cancers (Basel). 2020; 12(7). PMC: 7409333. DOI: 10.3390/cancers12071747. View

19.

DO S, Kim H, Kim K, Lee H, Do I, Kim D . Predictive and prognostic value of sphingosine kinase 1 expression in patients with invasive ductal carcinoma of the breast. Am J Transl Res. 2018; 9(12):5684-5695. PMC: 5752919. View

20.

Acharya S, Yao J, Li P, Zhang C, Lowery F, Zhang Q . Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2019; 79(16):4211-4226. PMC: 6697620. DOI: 10.1158/0008-5472.CAN-18-3803. View